Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.

Kyntra Bio (KYNB) reported Q2 2026 revenue of -$1.5M, a net income of $12.0M, and $95.7M in cash. Clinical trials for FG-3246 in prostate cancer and roxadustat in MDS showed progress. Operating expenses rose to $16.1M. Management expects cash to last into 2028 and is evaluating partnership options for roxadustat.

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues

Wells Fargo raised its price target for Accenture (NYSE:ACN) to $210 from $194, citing Q4 results and adjusted revenue/earnings estimates for 2027-2029. Accenture's stock trades at $212.30, with a Fair Value suggesting upside potential. Analysts highlight strong Q4 results, AI opportunities, and stable discretionary spending as key factors.

Nike (NKE) reported Q1 revenue of $11.2B, down 4% YoY, with EPS at 48 cents and gross margin at 42.8%. The company forecasted a high-single-digit revenue decline for fiscal 2027. Full-year EPS is expected to be $1.15-$1.35, excluding restructuring costs. The outlook reflects management's forecast, not completed results.

RBC Capital maintained its Sector Perform rating and $40 price target for Nike (NKE), citing deeper operational challenges and reduced earnings estimates. Nike's stock fell 9% after a revenue miss and weak guidance for fiscal 2027, with revenue expected to decline in the high single digits. Multiple analysts lowered their price targets, citing sales declines and slow turnaround progress. The stock trades at $35.15, near its 52-week low.